Clinical Trial Update: Hyperspectral Drusen Classification

View source ↗

Summary

Optina Diagnostics completed a clinical trial evaluating hyperspectral drusen classification for dry age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Snippet

Sponsor: Optina Diagnostics Inc. | Conditions: Dry Age Related Macular Degeneration | Status: COMPLETED